$321 Million is the total value of Vivo Capital, LLC's 22 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 21.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACRS | Aclaris therapeutics | $107,342,000 | +38.7% | 4,191,397 | 0.0% | 33.45% | +58.2% | |
| ASND | Ascendis Pharmaadr | $35,513,000 | +51.5% | 1,766,832 | 0.0% | 11.07% | +72.8% | |
| EIGR | Buy | Eiger BioPharmaceuticals | $23,929,000 | -24.5% | 1,787,091 | +11.7% | 7.46% | -13.9% |
| CDXS | Sell | Codexis, Inc. | $23,509,000 | +4.7% | 5,294,825 | -5.0% | 7.33% | +19.4% |
| NBRV | Nabriva Therapeutics AGadr | $22,219,000 | -6.0% | 3,151,700 | 0.0% | 6.92% | +7.3% | |
| AAAP | Advanced Accelerator Applications S.A. | $17,357,000 | +25.9% | 455,798 | 0.0% | 5.41% | +43.7% | |
| AGRX | Agile Therapeutics, Inc. | $14,099,000 | -8.3% | 2,019,955 | 0.0% | 4.39% | +4.7% | |
| RGNX | Regenxbio Inc. | $13,876,000 | +75.1% | 990,449 | 0.0% | 4.32% | +99.8% | |
| TRVN | Trevena, Inc. | $11,664,000 | +7.1% | 1,728,000 | 0.0% | 3.64% | +22.3% | |
| AIMT | Aimmune Therapeutics, Inc. | $11,445,000 | +38.6% | 763,009 | 0.0% | 3.57% | +58.2% | |
| CLCD | New | CoLucid Pharmaceuticals, Inc. | $8,584,000 | – | 225,000 | +100.0% | 2.68% | – |
| FOMX | New | Foamix Pharmaceuticals Ltd. | $7,917,000 | – | 855,000 | +100.0% | 2.47% | – |
| CAPN | Capnia, Inc. | $6,711,000 | -22.4% | 7,456,984 | 0.0% | 2.09% | -11.5% | |
| AKTX | Akari Therapeutics Plcadr | $4,492,000 | -36.9% | 527,842 | 0.0% | 1.40% | -28.0% | |
| DNAI | ProNAi Therapeutics, Inc. | $4,438,000 | -8.5% | 2,438,270 | 0.0% | 1.38% | +4.4% | |
| DVAX | Dynavax Technologies Corporation | $3,775,000 | -28.0% | 359,828 | 0.0% | 1.18% | -17.9% | |
| CBYL | Carbylan Therapeutics | $1,934,000 | -30.3% | 4,204,562 | 0.0% | 0.60% | -20.4% | |
| RVNC | ReVance Therapeutics, Inc. | $1,254,000 | +19.2% | 77,373 | 0.0% | 0.39% | +36.2% | |
| OCRX | Ocera Therapeutics, Inc. | $405,000 | +39.2% | 153,331 | 0.0% | 0.13% | +59.5% | |
| CAPNW | Capnia, Inc.warrant | $198,000 | -19.2% | 943,858 | 0.0% | 0.06% | -7.5% | |
| PTN | Palatin Technologies, Inc. | $148,000 | +43.7% | 234,909 | 0.0% | 0.05% | +64.3% | |
| ZSAN | Zosano Pharma Corp | $78,000 | -37.6% | 98,515 | 0.0% | 0.02% | -29.4% | |
| MEIP | Exit | MEI Pharma, Inc. | $0 | – | -1,101,129 | -100.0% | -0.41% | – |
| NERV | Exit | Minerva Neurosciences, Inc. | $0 | – | -200,000 | -100.0% | -0.56% | – |
| SGNT | Exit | Sagent Pharmaceuticals, Inc. | $0 | – | -6,495,416 | -100.0% | -26.57% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.